Comparison of the Pharmacokinetics of Tiotropium Delivered From Test Inhaler Products With A Reference Product

NCT03155204 | Completed Early Phase 1

• 1 other identifier: CSP-07-000039
• Study Type: interventional
• Target: 46
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to compare the absorption of four different inhalation products with the reference product in healthy volunteers.

Conditions

Healthy

Keywords

inhalation; LABA; corticosteroid

Outcome Measures

Primary Outcomes (1)

• Peak Plasma Concentration (Cmax)

  noncompartmental analysis

  24 hr

Secondary Outcomes (2)

• Adverse events

  24 hr

• Area Under the Plasma Concentration vs Time Curve (AUC)

  24 hr

Study Arms (5)

Test Product 1

EXPERIMENTAL

tiotropium pMDI 2 inhalations

Drug: tiotropium pMDI

Test Product 2

EXPERIMENTAL

tiotropium pMDI 2 inhalations

Drug: tiotropium pMDI

Test Product 3

EXPERIMENTAL

tiotropium pMDI 2 inhalations

Drug: tiotropium pMDI

Test Product 4

EXPERIMENTAL

tiotropium pMDI 2 inhalations

Drug: tiotropium pMDI

Commercial Product

ACTIVE COMPARATOR

tiotropium Respimat 2 inhalations

Drug: tiotropium pMDI

Interventions

tiotropium pMDI DRUG

inhalation

Also known as: Spiriva Respimat

Commercial Product; Test Product 1; Test Product 2; Test Product 3; Test Product 4

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy Volunteer
• Willing and able to give informed consent
• Willing to withhold all alcoholic beverages for 48 hours and all xanthine- containing foods and beverages for 24 hours prior to reporting to clinic
• Subjects must agree to use an adequate method of contraception from admission through 12 weeks after last administration

You may not qualify if:

• Evidence or history of clinically significant abnormalities or disease or chronic respiratory disorders
• Any presence or history of a clinically significant allergy including any adverse reaction to study drug
• History of drug or alcohol abuse within the past 2 years
• Smoked tobacco within the past 6 months or have a history of more than 10- pack years (number of packs smoked per day x number of years smoked)
• Donation or loss of greater than 400 mL of blood within the previous 3 months
• Have received any prescription medication within 4 weeks or investigational medication within 12 weeks of study (exception: contraceptives are permitted)
• Have received any non-prescription medication within 14 days prior to dosing (exception: paracetamol use within 2 days)
• Upper respiratory tract infection (excluding otitis media) within 14 days of the first study day, or lower respiratory tract infection within the last 3 months
• If female, nursing, lactating or pregnant
• Regular alcohol consumption in males \>21 units per week and females \>14 units per week (1 unit = ½ pint beer, 25 mL of 40% spirit or a 125 mL glass of wine)

Sponsors & Collaborators

• Solventum US LLC: lead
• 3M: collaborator

Study Sites (1)

3M Health Care

Loughborough, United Kingdom

Location

MeSH Terms

Conditions

Respiratory Aspiration

Condition Hierarchy (Ancestors)

Respiration Disorders; Respiratory Tract Diseases; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Victoria Sessions, PhD

  3M

  STUDY CHAIR

Study Design

• Study Type: interventional
• Phase: early phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 15, 2017
• First Posted: May 16, 2017
• Study Start: April 25, 2017
• Primary Completion: January 21, 2018
• Study Completion: March 19, 2018
• Last Updated: December 2, 2024

Record last verified: 2024-11

Data Sharing

• IPD Sharing: Will not share

Locations

GB (1)